Holen Sie sich die Stockscreener-App
12.90
5.49%
-0.75
Handel nachbörslich:
12.80
-0.10
-0.78%
Schlusskurs vom Vortag:
$13.65
Offen:
$13.65
24-Stunden-Volumen:
2.84M
Relative Volume:
1.13
Marktkapitalisierung:
$1.15B
Einnahmen:
$217.42M
Nettoeinkommen (Verlust:
$-243.25M
KGV:
-4.6151
EPS:
-2.7952
Netto-Cashflow:
$-278.35M
1W Leistung:
-24.07%
1M Leistung:
-25.35%
6M Leistung:
-45.82%
1J Leistung:
-14.29%
1-Tages-Spanne:
$12.81
$13.65
1-Wochen-Bereich:
$12.81
$16.95
52-Wochen-Spanne:
$12.81
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
12.90 | 1.15B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List - GlobeNewswire
Syndax Pharmaceuticals, Inc. (SNDX) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? - Simply Wall Street
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - TradingView
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PR Newswire
Syndax Pharmaceuticals Suffers Pipeline BlowSyndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $37.27, Implies 125% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownHere's What Happened - MarketBeat
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. - Barron's
Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed as Buy by HC Wainwright - MarketBeat
BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating - Yahoo Finance
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Syndax Pharmaceuticals (NasdaqGS:SNDX) Stock Forecast & Analyst Predictions - Simply Wall Street
Syndax Pharmaceuticals (SNDX) Stock Forecast and Price Target 2026 - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? - Yahoo Finance
Syndax Pharmaceuticals ends IPF development after Phase 2 axatilimab miss - Mugglehead Investment Magazine
SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Yahoo Finance
Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria - GuruFocus
Syndax Pharmaceuticals' Axatilimab Trial in Pulmonary Fibrosis Misses Primary Endpoint - Yahoo Finance
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development - Yahoo Finance
Syndax Pharmaceuticals stock tumbles on failed IPF trial - Yahoo Finance
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewswire
Possible Bearish Signals With Syndax Pharmaceuticals Insiders Disposing Stock - Moomoo
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Cash flow from investing activities of Syndax Pharmaceuticals Inc – HAN:1T3 - TradingView
Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX) - Seeking Alpha
Syndax Pharmaceuticals poised for growth with p... - Pluang
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors - BioWorld News
Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Syndax Pharmaceuticals Inc-Aktie (SNDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Jul 08 '26 |
Sale |
24.24 |
32,375 |
784,776 |
484,843 |
| MICHAEL METZGER | Director |
Jul 08 '26 |
Proposed Sale |
23.24 |
32,375 |
752,395 |
0 |
| Botwood Nicholas A.J. | Officer |
Jun 12 '26 |
Proposed Sale |
18.14 |
31,235 |
566,693 |
0 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Sale |
18.14 |
31,235 |
566,603 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Option Exercise |
13.82 |
31,235 |
431,668 |
92,120 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Sale |
18.00 |
34,280 |
617,040 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Option Exercise |
13.82 |
22,515 |
311,157 |
95,165 |
| Botwood Nicholas A.J. | Officer |
Jun 11 '26 |
Proposed Sale |
17.78 |
34,280 |
609,435 |
0 |
| Goldan Keith A. | Chief Financial Officer |
Jun 01 '26 |
Sale |
18.99 |
1,177 |
22,351 |
139,252 |
| Metzger Michael A | Chief Executive Officer |
Jun 01 '26 |
Sale |
18.99 |
6,847 |
130,025 |
484,843 |
1.60%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):